Abstract

Tamoxifen as adjuvant therapy for women with breast cancer decreases serum lipids and lipoproteins by its estrogenic agonist effects. We evaluated whether a novel antiestrogen, toremifene, has similar effects. Patients and Methods 49 postmenopausal early breast cancer patients were randomized to adjuvant tamoxifen or toremifene treatment groups. Total, LDL and HDL cholesterol, apolipoprotein A-I, A-II and B and Lp(a) were measured before treatment and after 12 months. Results Both antiestrogens reduced significantly serum total and LDL cholesterol and apo B levels. The response of HDL cholesterol to treatment was clearly different between the groups. Toremifene increased the HDL-Ievel 14% whereas tamoxifen decreased it 5% ( P = 0.001). Both Chol/HDL and LDL/HDL ratios fell more in the toremifene than tamoxifen group (P = 0.008; p = 0.03, respectively). Toremifene also increased apo A-I level ( P = 0.00007) and apo A-I/A-II ratio ( P = 0.018). In both tamoxifen and toremifene treatment groups Lp(a) concentration fell significantly (change: 34% vs 41%). Conclusion These results provide positive evidence that toremifene has highly antiatherogenic properties with an exceptional potency to improve all lipoproteins which are associated with increased coronary heart disease risk.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.